The Expression and Prognostic Value of the Peripheral Cannabinoid Receptor in Hermatological Malignancies

Non-Hodgkin’s lymphoma’s (NHLs) are a heterogeneous group of hematological malignancies with a large variation in clinical presentation, morphological appearance and prognosis. The NHLs make up the largest group (40-50%) of all hematological malignancies. In 2007, 17.700 people in the Netherlands had a non-Hodgkin’s lymphoma. Of these cases, 1.2/1000 was male and 1.2/1000 was female. The number of newly diagnosed NHL was 2800. In the same year, 1061 succumbed to the disease (585 male, 476 female)1. NHLs almost always arise from cells of the immune system resulting, in either B-cell or T-cell lymphomas. Most (approximately 85%) NHLs arise from their normal B-cell counterparts whereas a minority (approximately 15%) is derived from T-cells. Of the NHLs, approximately 65% arise in lymph nodes (nodal type), whereas the remaining 35% can arise in any organ (extra-nodal type). The most recent WHO classifi cation contains about 50 different (clinico-pathological) entities. Each entity is considered to have a normal physiological counterpart refl ecting the various differentiation stages in the lymphoid organs or bone marrow

Paranthidium, Anthidiellum, and Hypanthidium

9 p. ; 24 cm.Includes bibliographical references

Prostate cancer-associated thrombotic microangiopathy: A case report and review of the literature

Background: Thrombotic microangiopathy (TMA) is a rare and life-threatening complication of prostate carcinoma. Whether plasma exchange has a role in treatment remains a subject of debate. Here we present a case followed by a systematic review of the literature on this subject. Case report: We describe a 69-year old patient presenting with TMA, which was associated with an underlying metastatic prostate carcinoma. We conducted a search of similar cases in literature. Results: Our patient was treated and responded well on plasma exchange. Systematic review of the literature showed 17 additional cases of TMA associated with prostate carcinoma of which eleven were treated with plasma exchange with mostly good response. Conclusion: Based on current data we cannot exclude a potential role for plasma exchange in prostate cancer associated TMA

Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials

Purpose: Until now molecular biologic techniques have not been easily used in daily clinical practice to stratify patients for therapeutic purposes. Therefore, we have investigated the prognostic relevance of the immunohistochemical (IHC) germinal center B-cell (GCB) versus non-GCB diffuse large B-cell lymphoma (DLBCL) subtypes. Patient; and Methods: We have analyzed tumor samples from patients treated in 2 prospective multicenter phase III trials, ie HOVON 25 (patients >= 65 years, n = 153) and HOVON 26 (patient

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.

Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a phase II trial specifically for frail patients, evaluating the efficacy and tolerability of ixazomib-daratumumab-low-dose-dexamethasone (Ixa-Dara-dex). Sixty-five patients, who were frail according to the International Myeloma Working Group frailty index, were treated with nine induction cycles Ixa-Dara-dex followed by maintenance with Ixa-Dara for a maximum of 2 years. The overall response rate on induction therapy was 78%. After a median follow-up of 22.9 months, median progression-free survival (PFS) was 13.8 months and 12-month overall survival (OS) was 78%. Median PFS and 12-month OS were 21.6 months and 92% in patients who were frail based on age > 80 years alone, versus 13.8 months and 78%, and 10.1 months and 70% in patients who were frail based on additional frailty parameters either ≤ 80 or > 80 years of age, respectively. In 51% of patients, induction therapy had to be discontinued prematurely, of which 6% because of noncompliance to study treatment, 9% because of toxicity, and 9% because of death (8% within 2 months, of which 80% because of toxicity). Quality of life improved during induction treatment, being clinically meaningful already after three induction cycles. Ixa-Dara-dex lead to a high response rate and improved quality of life. However, treatment discontinuation because of toxicity and early mortality, negatively influencing PFS and OS, remains a concern in frail patients. The outcome was heterogeneous across frail subpopulations. This should be taken into account in the design and interpretation of future studies in frail patients, to pave the way for more precise treatment guidance